The exploration of anxiety-like behavior (elevated plus maze and open field test) at several time points after withdrawal of ethanol intake following an intraperitoneal administration of an acute ethanol dose (4 g/kg) revealed a more pronounced alteration of anxiety between 12–18 h [62]; the acute administration of an A1R agonist (CCPA: 0.05, 0.125, and 0.25 intraperitoneally) reduced of anxiogenic-like behavior in the elevated plus-maze, whereas the administration of the selective A2AR agonist (DPMA) had no effect. The gene discussed is ADORA2A; the disease is Anxiety.